Contact
searchSearch
HMP Global
Login

Pancreatic Cancer Specialty Channel

Conference Coverage
Durvalumab Plus Olaparib Demonstrates Strong Clinical Promise for Metastatic Pancreatic Cancer
01/12/2026
Stephanie Holland
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study...
01/12/2026
Oncology
Quiz
Neoadjuvant FOLFIRINOX for Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma
11/25/2025
True or False: In the phase 3 PREOPANC-2 trial, neoadjuvant FOLFIRINOX significantly improved overall survival compared with neoadjuvant gemcitabine-based chemoradiotherapy in patients with resectable or borderline resectable pancreatic...
True or False: In the phase 3 PREOPANC-2 trial, neoadjuvant FOLFIRINOX significantly improved overall survival compared with neoadjuvant gemcitabine-based chemoradiotherapy in patients with resectable or borderline resectable pancreatic...
True or False: In the phase 3...
11/25/2025
Oncology
News
Eryaspase Demonstrates No Survival Benefit for Patients With Advanced PDAC: Phase 3 TRYBECA-1 Trial
11/20/2025
Emily Estrada
The addition of eryaspase to standard chemotherapy did not improve survival outcomes for patients with advanced pancreatic ductal adenocarcinoma, according to results from the phase 3 TRYBECA-1 trial.
The addition of eryaspase to standard chemotherapy did not improve survival outcomes for patients with advanced pancreatic ductal adenocarcinoma, according to results from the phase 3 TRYBECA-1 trial.
The addition of eryaspase to...
11/20/2025
Oncology
News
Microwave Ablation Plus Dual Checkpoint Inhibition Enhances Immune Response in Locally Advanced Pancreatic Ductal Adenocarcinoma
11/19/2025
Stephanie Holland
Combining dual durvalumab and tremelimumab with microwave tumor ablation and chemotherapy demonstrated encouraging progression-free survival and potential immune modulation among patients with unresectable, non-metastatic, locally advanced...
Combining dual durvalumab and tremelimumab with microwave tumor ablation and chemotherapy demonstrated encouraging progression-free survival and potential immune modulation among patients with unresectable, non-metastatic, locally advanced...
Combining dual durvalumab and...
11/19/2025
Oncology
News
Extending Pre-Operative Chemotherapy May Be Preferable for Resectable and Borderline Resectable Pancreatic Cancer
10/23/2025
Stephanie Holland
Results from the phase 3 CASSANDRA trial demonstrate that extending pre-operative chemotherapy may be preferable to short-course chemotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma.
Results from the phase 3 CASSANDRA trial demonstrate that extending pre-operative chemotherapy may be preferable to short-course chemotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma.
Results from the phase 3...
10/23/2025
Oncology
News
PANOVA-3 Post-Hoc Analyses Highlight Predictors of Benefit With TTFields Therapy in Pancreatic Adenocarcinoma
10/19/2025
Janelle Bradley
Higher device adherence and reductions in CA 19-9 levels may serve as early indicators of improved survival in patients with unresectable locally advanced pancreatic adenocarcinoma treated with TTFields plus gemcitabine and nab-paclitaxel,...
Higher device adherence and reductions in CA 19-9 levels may serve as early indicators of improved survival in patients with unresectable locally advanced pancreatic adenocarcinoma treated with TTFields plus gemcitabine and nab-paclitaxel,...
Higher device adherence and...
10/19/2025
Oncology
News
Neoadjuvant FOLFIRINOX Did Not Significantly Improve Overall Survival Among Patients With Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma
10/14/2025
Stephanie Holland
Results from the phase 3 PREOPANC-2 trial found that neoadjuvant FOLFIRINOX did not significantly improve overall survival results compared to gemcitabine-based chemoradiotherapy among patients with resectable or borderline resectable...
Results from the phase 3 PREOPANC-2 trial found that neoadjuvant FOLFIRINOX did not significantly improve overall survival results compared to gemcitabine-based chemoradiotherapy among patients with resectable or borderline resectable...
Results from the phase 3...
10/14/2025
Oncology
Quiz
Impact of Tumor Treating Fields Plus Chemotherapy on Quality of Life for Patients With Pancreatic Cancer
10/07/2025
Do you know the primary finding regarding pain and quality of life outcomes from the PANOVA-3 trial evaluating the addition of tumor treating fields to gemcitabine/nab-paclitaxel? Take our quick quiz to find out!
Do you know the primary finding regarding pain and quality of life outcomes from the PANOVA-3 trial evaluating the addition of tumor treating fields to gemcitabine/nab-paclitaxel? Take our quick quiz to find out!
Do you know the primary finding...
10/07/2025
Oncology
News
GVAX Combination and Stereotactic Body Radiotherapy Demonstrates Clinical Promise in Borderline Resectable Pancreatic Cancer
09/29/2025
Stephanie Holland
According to results from a phase 2 study, the addition of combined immunotherapy (GVAX plus cyclophosphamide and nivolumab) and stereotactic body radiotherapy demonstrated promising efficacy among patients with borderline resectable...
According to results from a phase 2 study, the addition of combined immunotherapy (GVAX plus cyclophosphamide and nivolumab) and stereotactic body radiotherapy demonstrated promising efficacy among patients with borderline resectable...
According to results from a...
09/29/2025
Oncology
News
FOLFIRINOX Compared to Gemcitabine Plus Nab-Paclitaxel For Pancreatic Cancer
09/29/2025
Stephanie Holland
According to results from a real-world study, FOLFIRINOX significantly improved survival outcomes compared to gemcitabine plus nab-paclitaxel among patients with borderline resectable pancreatic cancer.
According to results from a real-world study, FOLFIRINOX significantly improved survival outcomes compared to gemcitabine plus nab-paclitaxel among patients with borderline resectable pancreatic cancer.
According to results from a...
09/29/2025
Oncology
Quiz
Tocilizumab Plus Gemcitabine and Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer
09/23/2025
In the phase 2 PATCO trial assessing the addition of tocilizumab to gemcitabine plus nab-paclitaxel among patients with advanced pancreatic cancer, which statement best reflects the implications for clinical practice?
In the phase 2 PATCO trial assessing the addition of tocilizumab to gemcitabine plus nab-paclitaxel among patients with advanced pancreatic cancer, which statement best reflects the implications for clinical practice?
In the phase 2 PATCO trial...
09/23/2025
Oncology

News

Conference Coverage
Durvalumab Plus Olaparib Demonstrates Strong Clinical Promise for Metastatic Pancreatic Cancer
01/12/2026
Stephanie Holland
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study...
01/12/2026
Oncology
News
Eryaspase Demonstrates No Survival Benefit for Patients With Advanced PDAC: Phase 3 TRYBECA-1 Trial
11/20/2025
Emily Estrada
The addition of eryaspase to standard chemotherapy did not improve survival outcomes for patients with advanced pancreatic ductal adenocarcinoma, according to results from the phase 3 TRYBECA-1 trial.
The addition of eryaspase to standard chemotherapy did not improve survival outcomes for patients with advanced pancreatic ductal adenocarcinoma, according to results from the phase 3 TRYBECA-1 trial.
The addition of eryaspase to...
11/20/2025
Oncology
News
Microwave Ablation Plus Dual Checkpoint Inhibition Enhances Immune Response in Locally Advanced Pancreatic Ductal Adenocarcinoma
11/19/2025
Stephanie Holland
Combining dual durvalumab and tremelimumab with microwave tumor ablation and chemotherapy demonstrated encouraging progression-free survival and potential immune modulation among patients with unresectable, non-metastatic, locally advanced...
Combining dual durvalumab and tremelimumab with microwave tumor ablation and chemotherapy demonstrated encouraging progression-free survival and potential immune modulation among patients with unresectable, non-metastatic, locally advanced...
Combining dual durvalumab and...
11/19/2025
Oncology
News
Extending Pre-Operative Chemotherapy May Be Preferable for Resectable and Borderline Resectable Pancreatic Cancer
10/23/2025
Stephanie Holland
Results from the phase 3 CASSANDRA trial demonstrate that extending pre-operative chemotherapy may be preferable to short-course chemotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma.
Results from the phase 3 CASSANDRA trial demonstrate that extending pre-operative chemotherapy may be preferable to short-course chemotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma.
Results from the phase 3...
10/23/2025
Oncology
News
PANOVA-3 Post-Hoc Analyses Highlight Predictors of Benefit With TTFields Therapy in Pancreatic Adenocarcinoma
10/19/2025
Janelle Bradley
Higher device adherence and reductions in CA 19-9 levels may serve as early indicators of improved survival in patients with unresectable locally advanced pancreatic adenocarcinoma treated with TTFields plus gemcitabine and nab-paclitaxel,...
Higher device adherence and reductions in CA 19-9 levels may serve as early indicators of improved survival in patients with unresectable locally advanced pancreatic adenocarcinoma treated with TTFields plus gemcitabine and nab-paclitaxel,...
Higher device adherence and...
10/19/2025
Oncology
News
Neoadjuvant FOLFIRINOX Did Not Significantly Improve Overall Survival Among Patients With Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma
10/14/2025
Stephanie Holland
Results from the phase 3 PREOPANC-2 trial found that neoadjuvant FOLFIRINOX did not significantly improve overall survival results compared to gemcitabine-based chemoradiotherapy among patients with resectable or borderline resectable...
Results from the phase 3 PREOPANC-2 trial found that neoadjuvant FOLFIRINOX did not significantly improve overall survival results compared to gemcitabine-based chemoradiotherapy among patients with resectable or borderline resectable...
Results from the phase 3...
10/14/2025
Oncology
News
GVAX Combination and Stereotactic Body Radiotherapy Demonstrates Clinical Promise in Borderline Resectable Pancreatic Cancer
09/29/2025
Stephanie Holland
According to results from a phase 2 study, the addition of combined immunotherapy (GVAX plus cyclophosphamide and nivolumab) and stereotactic body radiotherapy demonstrated promising efficacy among patients with borderline resectable...
According to results from a phase 2 study, the addition of combined immunotherapy (GVAX plus cyclophosphamide and nivolumab) and stereotactic body radiotherapy demonstrated promising efficacy among patients with borderline resectable...
According to results from a...
09/29/2025
Oncology
News
FOLFIRINOX Compared to Gemcitabine Plus Nab-Paclitaxel For Pancreatic Cancer
09/29/2025
Stephanie Holland
According to results from a real-world study, FOLFIRINOX significantly improved survival outcomes compared to gemcitabine plus nab-paclitaxel among patients with borderline resectable pancreatic cancer.
According to results from a real-world study, FOLFIRINOX significantly improved survival outcomes compared to gemcitabine plus nab-paclitaxel among patients with borderline resectable pancreatic cancer.
According to results from a...
09/29/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Second-Line Irinotecan Liposome-Based Treatment Modalities Demonstrate Efficacy and Safety Among Patients With Advanced Unresectable Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a...
08/28/2025
Oncology

Interactive Features

Quiz
Neoadjuvant FOLFIRINOX for Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma
11/25/2025
True or False: In the phase 3 PREOPANC-2 trial, neoadjuvant FOLFIRINOX significantly improved overall survival compared with neoadjuvant gemcitabine-based chemoradiotherapy in patients with resectable or borderline resectable pancreatic...
True or False: In the phase 3 PREOPANC-2 trial, neoadjuvant FOLFIRINOX significantly improved overall survival compared with neoadjuvant gemcitabine-based chemoradiotherapy in patients with resectable or borderline resectable pancreatic...
True or False: In the phase 3...
11/25/2025
Oncology
Quiz
Impact of Tumor Treating Fields Plus Chemotherapy on Quality of Life for Patients With Pancreatic Cancer
10/07/2025
Do you know the primary finding regarding pain and quality of life outcomes from the PANOVA-3 trial evaluating the addition of tumor treating fields to gemcitabine/nab-paclitaxel? Take our quick quiz to find out!
Do you know the primary finding regarding pain and quality of life outcomes from the PANOVA-3 trial evaluating the addition of tumor treating fields to gemcitabine/nab-paclitaxel? Take our quick quiz to find out!
Do you know the primary finding...
10/07/2025
Oncology
Quiz
Tocilizumab Plus Gemcitabine and Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer
09/23/2025
In the phase 2 PATCO trial assessing the addition of tocilizumab to gemcitabine plus nab-paclitaxel among patients with advanced pancreatic cancer, which statement best reflects the implications for clinical practice?
In the phase 2 PATCO trial assessing the addition of tocilizumab to gemcitabine plus nab-paclitaxel among patients with advanced pancreatic cancer, which statement best reflects the implications for clinical practice?
In the phase 2 PATCO trial...
09/23/2025
Oncology
Quiz
Quiz: Is FOLFIRINOX a Superior Treatment for Patients With Resectable Pancreatic Cancer?
09/08/2021
True or false: Results from the SWOG 1505 trial indicate that FOLFIRINOX was a superior therapy choice compared with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer.
True or false: Results from the SWOG 1505 trial indicate that FOLFIRINOX was a superior therapy choice compared with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer.
True or false: Results from the...
09/08/2021
Oncology
Quiz
Quiz: Do Molecularly-Matched Therapies Improve OS for Pancreatic Cancer?
08/12/2021
Molecularly-matched treatments for patients with pancreatic cancer significantly increase overall survival.
Molecularly-matched treatments for patients with pancreatic cancer significantly increase overall survival.
Molecularly-matched treatments...
08/12/2021
Oncology
Quiz
Quiz: What is the Median Age of Patients Diagnosed with Pancreatic Cancer?
08/03/2021
True or False: The median age of patients who are diagnosed with pancreatic cancer is 70 years old.
True or False: The median age of patients who are diagnosed with pancreatic cancer is 70 years old.
True or False: The median age of...
08/03/2021
Oncology
Test Your Knowledge
Quiz: Which Combination Benefits Patients with Mesothelin-Expressing Solid Tumors?
08/06/2020
Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?
Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?
Which combination yielded...
08/06/2020
Oncology
Test Your Knowledge
Quiz: Adjuvant Chemoradiation for High-Risk Pancreatic Cancer
09/26/2019
True or False: Adding radiation to adjuvant chemotherapy has been shown to encourage a clinically small but meaningful increase in survival.
True or False: Adding radiation to adjuvant chemotherapy has been shown to encourage a clinically small but meaningful increase in survival.
True or False: Adding radiation...
09/26/2019
Oncology
Test Your Knowledge
Quiz: Durvalumab Combo Therapy for Pancreatic Cancer
08/27/2019
Durvalumab therapy plus _______ was well-tolerated but demonstrated poor activity in a study of patients with metastatic pancreatic ductal adenocarcinoma.
Durvalumab therapy plus _______ was well-tolerated but demonstrated poor activity in a study of patients with metastatic pancreatic ductal adenocarcinoma.
Durvalumab therapy plus _______...
08/27/2019
Oncology
Test Your Knowledge
Quiz: Can Hydroxychloroquine Improve OS in Patients With Pancreatic Cancer?
07/09/2019
True or false: In a recent study, adding hydroxychloroquine to chemotherapy improved overall survival in patients with metastatic pancreatic cancer.
True or false: In a recent study, adding hydroxychloroquine to chemotherapy improved overall survival in patients with metastatic pancreatic cancer.
True or false: In a recent...
07/09/2019
Oncology

Recent News

Conference Coverage
Durvalumab Plus Olaparib Demonstrates Strong Clinical Promise for Metastatic Pancreatic Cancer
01/12/2026
Stephanie Holland
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study...
01/12/2026
Oncology
News
Eryaspase Demonstrates No Survival Benefit for Patients With Advanced PDAC: Phase 3 TRYBECA-1 Trial
11/20/2025
Emily Estrada
The addition of eryaspase to standard chemotherapy did not improve survival outcomes for patients with advanced pancreatic ductal adenocarcinoma, according to results from the phase 3 TRYBECA-1 trial.
The addition of eryaspase to standard chemotherapy did not improve survival outcomes for patients with advanced pancreatic ductal adenocarcinoma, according to results from the phase 3 TRYBECA-1 trial.
The addition of eryaspase to...
11/20/2025
Oncology
News
Microwave Ablation Plus Dual Checkpoint Inhibition Enhances Immune Response in Locally Advanced Pancreatic Ductal Adenocarcinoma
11/19/2025
Stephanie Holland
Combining dual durvalumab and tremelimumab with microwave tumor ablation and chemotherapy demonstrated encouraging progression-free survival and potential immune modulation among patients with unresectable, non-metastatic, locally advanced...
Combining dual durvalumab and tremelimumab with microwave tumor ablation and chemotherapy demonstrated encouraging progression-free survival and potential immune modulation among patients with unresectable, non-metastatic, locally advanced...
Combining dual durvalumab and...
11/19/2025
Oncology
News
Extending Pre-Operative Chemotherapy May Be Preferable for Resectable and Borderline Resectable Pancreatic Cancer
10/23/2025
Stephanie Holland
Results from the phase 3 CASSANDRA trial demonstrate that extending pre-operative chemotherapy may be preferable to short-course chemotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma.
Results from the phase 3 CASSANDRA trial demonstrate that extending pre-operative chemotherapy may be preferable to short-course chemotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma.
Results from the phase 3...
10/23/2025
Oncology
News
Neoadjuvant FOLFIRINOX Did Not Significantly Improve Overall Survival Among Patients With Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma
10/14/2025
Stephanie Holland
Results from the phase 3 PREOPANC-2 trial found that neoadjuvant FOLFIRINOX did not significantly improve overall survival results compared to gemcitabine-based chemoradiotherapy among patients with resectable or borderline resectable...
Results from the phase 3 PREOPANC-2 trial found that neoadjuvant FOLFIRINOX did not significantly improve overall survival results compared to gemcitabine-based chemoradiotherapy among patients with resectable or borderline resectable...
Results from the phase 3...
10/14/2025
Oncology
News
GVAX Combination and Stereotactic Body Radiotherapy Demonstrates Clinical Promise in Borderline Resectable Pancreatic Cancer
09/29/2025
Stephanie Holland
According to results from a phase 2 study, the addition of combined immunotherapy (GVAX plus cyclophosphamide and nivolumab) and stereotactic body radiotherapy demonstrated promising efficacy among patients with borderline resectable...
According to results from a phase 2 study, the addition of combined immunotherapy (GVAX plus cyclophosphamide and nivolumab) and stereotactic body radiotherapy demonstrated promising efficacy among patients with borderline resectable...
According to results from a...
09/29/2025
Oncology
News
FOLFIRINOX Compared to Gemcitabine Plus Nab-Paclitaxel For Pancreatic Cancer
09/29/2025
Stephanie Holland
According to results from a real-world study, FOLFIRINOX significantly improved survival outcomes compared to gemcitabine plus nab-paclitaxel among patients with borderline resectable pancreatic cancer.
According to results from a real-world study, FOLFIRINOX significantly improved survival outcomes compared to gemcitabine plus nab-paclitaxel among patients with borderline resectable pancreatic cancer.
According to results from a...
09/29/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Second-Line Irinotecan Liposome-Based Treatment Modalities Demonstrate Efficacy and Safety Among Patients With Advanced Unresectable Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a...
08/28/2025
Oncology
News
Addition of Tocilizumab to First-Line Gemcitabine Plus Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.
According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.
According to results from the...
08/28/2025
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use